

WEB TABLE I STUDIES ON HEPATOBLASTOMA FROM INDIA

Institute	Time Period	Patient Number	Median Age	% Males	Stage of Disease	Preoperative Chemotherapy	Response to Chemotherapy	Resected	Treatment Related Mortality	Progression of Disease	Survival
GCRI, Ahmedabad	1992 to 2000	32	Not specified	72%	Not specified	32/32 (100%) (7/32 CYCL/VCR/FU 25/32 PLADO)	Not specified	10/12* (83%)	6/12* (50%)	2/12* (17%)	EFS 33%* (duration of FU not specified)
Lilavati Hospital, Mumbai	Not known	5	18 months	100%	Not specified	5/5 (100%) (3/5 PLADO 2/5 CDDP/VCR/FU)	5/5 (100%)	5/5 (100%)	0/5 (0%)	0/5 (0%)	EFS 100% (FU 24 to 48 months)
AIIMS, New Delhi	1999 to 2006	36	12 months	Not known	PRETEXT I=0, II=23, III=7, IV=6	34/36 (94%) (All PLADO)	27/34 (79%)	30/36 (83%)	Not known	8/36 (23%)	OS [†] for SR 85%, HR 37.5% (duration of FU not specified)
BJ Wadia Hospital, Mumbai	1996 to 2006	21	<12 months	52%	PRETEXT I=1, II=8, III=4, IV=8	Not specified (All PLADO)	Not specified	8/9‡ (89%)	2/9‡ (22%)	2/9‡ (22%)	EFS 55%‡ (median FU 60 months)
RCC, Thiruvnanthapuram	1996 to 2005	20	Not specified	Not known	Not specified	17/20 (85%) (All PLADO)	Not specified	20/20 (100%)	6/20 (30%)	3/20 (15%)	EFS 55% (duration of FU not specified)
TMH, Mumbai	2000 to 2007	18	18 months	67%	POG I=16, II=2, III=0, IV=0	16/18 (88.9%) (All CDDP/VCR/FU)	Not specified	18/18 (100%)	3/18 (17%)	3/18 (17%)	EFS 67% (median FU 80 months)
KMIO, Bangalore	1997 to 2004	12	24 months	75%	POG I=7, II=2, III=0, IV=0, Not known = 3	12/12 (100%) (All PLADO)	9/9§ (100%)	9/9§ (100%)	0/9§ (0%)	0/9§ (0%)	EFS 100%§ (FU 24-90 months)
Cancer Institute, Chennai	2000 to 2007	13	12 months	77%	PRETEXT I=1, II=6, III=5, IV=1	9/13 (69%) (All PLADO)	6/7 (86%)	10/11 (91%)	2/13 (15%)	1/13 (8%)	EFS 77% (median FU 63 months)

*excluding 20 who abandoned; †Event Free Survival not given; ‡excluding 12 who abandoned; §excluding 3 who abandoned; ||2 not assessed due to mortality early in treatment; AIIMS: All India Institute of Medical Sciences; CDDP/VCR/FU: Cisplatin, Vincristine, Fluorouracil; CYCL/VCR/FU: Cyclophosphamide, Vincristine, Fluorouracil; EFS: Event Free Survival; FU: Follow-up; GCRI: Gujarat Cancer Research Institute; HR: High Risk; KMIO - Kidwai Memorial Institute of Oncology; OS: Overall Survival; PLADO: Cisplatin, Doxorubicin; POG: Pediatric Oncology Group; PRETEXT: Pre-treatment tumour extension system; RCC: Regional Cancer Centre; SR: Standard Risk; TMH: Tata Memorial Hospital.